Royalty Pharma plc — Director's Dealing 2023

May 25, 2023

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Royalty Pharma plc (RPRX)
CIK: 0001802768
Period of Report: 2023-05-24

Reporting Person: Legorreta Pablo G. (Director, CEO, Chairman of the Board, 10% Owner)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2023-05-24	Class A ordinary shares	P	150000	$32.2496	Acquired	380000	Indirect

Holdings (Non-Derivative)

Security	Shares	Ownership
Class A ordinary shares	63795	Direct
Class A ordinary shares	460139	Indirect
Class A ordinary shares	1284590	Indirect
Class A ordinary shares	41306	Indirect
Class A ordinary shares	10000	Indirect
Class A ordinary shares	10000	Indirect
Class A ordinary shares	123310	Indirect
Class A ordinary shares	118500	Indirect
Class A ordinary shares	1040410	Indirect
Class A ordinary shares	6930	Indirect

Footnotes

F1: Represents shares acquired by the reporting person in open market transactions as part of the reporting person's previously disclosed intention to purchase up to $50 million of the issuer's Class A ordinary shares, as announced in the issuer's press release on March 27, 2023 regarding the issuer's $1.0 billion share repurchase program.

F2: The price reported in Column 4 is a weighted average price. The reported securities were purchased in multiple transactions at prices ranging from $32.20 to $32.28. The reporting person undertakes to provide to the issuer, any security holder of the issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within such range.